<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The IgG response to Epstein-Barr virus (EBV) early antigens [BHRF1 (p 17.1), the <z:mp ids='MP_0001799'>viral</z:mp> homologue of bcl-2, and BMRF1 (p50.10), a DNA binding protein] was measured in patients with <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> to see whether there was any association with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sj√∂gren's syndrome</z:e> (SS), <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who did not have a <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> individuals were tested for the presence of anti-EA <z:chebi fb="7" ids="16670">peptide</z:chebi> antibodies by ELISA </plain></SENT>
<SENT sid="2" pm="."><plain>Whereas antibodies to early EBV <z:chebi fb="7" ids="16670">peptides</z:chebi> were detected only in one <z:mpath ids='MPATH_458'>normal</z:mpath> individual, patients with <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>, especially those with either SS and/or <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, had a much higher frequency of antibody detection </plain></SENT>
<SENT sid="3" pm="."><plain>Antibodies to BMRF1 p50.10 were found in 7-50% of patients, and to BHRF1 p17.1 in 4-27%, depending on the group studied </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> lacking a <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> had a 2-fold lower frequency of anti-BHRF1 antibodies, compared to the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> plus <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic disease</z:e> group </plain></SENT>
<SENT sid="5" pm="."><plain>The increased immune response to the EBV EA proteins in the <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> probably reflects the presence of reactivated virus, and the BHRF1 protein (the <z:mp ids='MP_0001799'>viral</z:mp> homologue to bcl-2) could, via inhibiting <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, contribute to the lymphoproliferative nature of these diseases </plain></SENT>
</text></document>